Hypoxia-Inducible Factor-Proline Hydroxylase Inhibitor in the Treatment of Renal Anemia
Background: Anemia is a common complication in CKD patients. Despite the use of iron and erythropoietin-stimulating agents, the control rate of anemia in CKD is not satisfying. Novel drugs are needed for anemia correction. Summary: HIF-PHI, hypoxia-inducible factor-proline hydroxylase inhibitor, a n...
Main Authors: | Xiaofan Hu, Jingyuan Xie, Nan Chen |
---|---|
Format: | Article |
Language: | English |
Published: |
Karger Publishers
2020-12-01
|
Series: | Kidney Diseases |
Subjects: | |
Online Access: | https://www.karger.com/Article/FullText/510587 |
Similar Items
-
Downregulation of Proline Hydroxylase 2 and Upregulation of Hypoxia-Inducible Factor 1α are Associated with Endometrial Cancer Aggressiveness
by: Zhu C, et al.
Published: (2019-11-01) -
Hypoxia-inducible factor for the treatment of anemia in chronic kidney disease
by: O.O. Melnyk
Published: (2018-10-01) -
Hypoxia-Inducible Factor and Its Role in the Management of Anemia in Chronic Kidney Disease
by: Joshua M. Kaplan, et al.
Published: (2018-01-01) -
Hypoxia Induced Factor in Chronic Kidney Disease: Friend or Foe?
by: Weiying Li, et al.
Published: (2018-01-01) -
Studies on the selectivity of proline hydroxylases reveal new substrates including bicycles
by: Smart, T.J., et al.
Published: (2020)